Linda F Thompson Selected Research

Linda F Thompson Research Topics

Disease

9	Neoplasms (Cancer) 01/2021 - 02/2005
6	Inflammation (Inflammations) 05/2012 - 01/2004
5	Hypoxia (Hypoxemia) 02/2008 - 10/2002
3	Fibrosis (Cirrhosis) 01/2017 - 04/2006
3	Systemic Lupus Erythematosus (Libman-Sacks Disease) 07/2014 - 10/2009
3	Human Influenza (Influenza) 12/2011 - 08/2011
2	Breast Neoplasms (Breast Cancer) 01/2021 - 02/2005
2	Pneumonia (Pneumonitis) 01/2017 - 04/2006
2	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2013 - 05/2012
2	Lung Injury 10/2011 - 04/2006
2	Severe combined immunodeficiency due to adenosine deaminase deficiency 06/2008 - 08/2002
1	Corneal Injuries 07/2020
1	Brain Neoplasms (Brain Tumor) 01/2019
1	Glioblastoma (Glioblastoma Multiforme) 01/2019
1	Neoplasm Metastasis (Metastasis) 01/2014
1	Hematologic Neoplasms (Hematological Malignancy) 01/2013
1	Sepsis (Septicemia) 10/2011
1	Infections 10/2011
1	Acute Lung Injury 01/2011
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 07/2008
1	Multiple Sclerosis 07/2008
1	Infarction (Infarctions) 03/2007
1	Myocardial Ischemia (Ischemic Heart Diseases) 03/2007
1	Ischemia 03/2007

Drug/Important Bio-Agent (IBA)

16	Adenosine (Adenocard)FDA LinkGeneric 01/2019 - 12/2004
10	5'-Nucleotidase (5' Nucleotidase)IBA 01/2016 - 10/2002
6	Purinergic P1 Receptors (Adenosine Receptor)IBA 01/2019 - 01/2004
4	Adenosine Triphosphate (ATP)IBA 05/2012 - 10/2002
3	Adenosine Monophosphate (AMP)IBA 03/2010 - 10/2002
3	Oxygen (Dioxygen)IBA 02/2008 - 10/2002
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2006
2	Adenosine DeaminaseIBA 01/2016 - 09/2006
2	AntibodiesIBA 01/2016 - 10/2009
2	CytokinesIBA 07/2014 - 10/2011
2	Adenine NucleotidesIBA 12/2004 - 10/2002
2	Adenosine Diphosphate (ADP)IBA 12/2004 - 10/2002
1	Immune Checkpoint InhibitorsIBA 01/2021
1	Annexin A5IBA 01/2021
1	Carbon Nanotubes (Carbon Nanotube)IBA 01/2021
1	SS-A antibodiesIBA 07/2020
1	EnzymesIBA 01/2019
1	Hyaluronic Acid (Hyaluronan)IBA 01/2017
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 07/2014
1	Purinergic P1 Receptor AntagonistsIBA 01/2014
1	B-Cell Activating FactorIBA 12/2011
1	InterferonsIBA 12/2011
1	AutoantibodiesIBA 12/2011
1	hydroxide ionIBA 12/2011
1	25-hydroxyvitamin DIBA 12/2011
1	Peroxidase (Myeloperoxidase)IBA 10/2011
1	Subunit VaccinesIBA 10/2011
1	Neuraminidase (Sialidase)IBA 10/2011
1	VaccinesIBA 10/2011
1	Prednisone (Sone)FDA LinkGeneric 08/2011
1	beta-apocarotenoid-14',13'-dioxygenase (ADO)IBA 01/2011
1	AllergensIBA 01/2011
1	EndotoxinsIBA 01/2011
1	Viral ProteinsIBA 10/2009
1	Surface Antigens (Surface Antigen)IBA 10/2009
1	deoxyribonucleoside kinasesIBA 06/2008
1	Small Interfering RNA (siRNA)IBA 02/2008
1	acetamideIBA 02/2008
1	1-propyl-8-(4-sulfophenyl)xanthineIBA 02/2008
1	CarrageenanIBA 05/2007
1	Messenger RNA (mRNA)IBA 09/2006
1	Pentostatin (Nipent)FDA LinkGeneric 09/2006
1	Bleomycin (Blenoxane)FDA LinkGeneric 04/2006
1	indium-bleomycinIBA 04/2006
1	nucleotidaseIBA 04/2006
1	Biological ProductsIBA 02/2005
1	ORALIT (ORS)IBA 02/2005
1	NucleotidesIBA 12/2004
1	Purinergic P1 Receptor AgonistsIBA 12/2004
1	4-O-carboxymethylascochlorinIBA 10/2002
1	LuciferasesIBA 10/2002
1	Antisense OligonucleotidesIBA 10/2002
1	alpha,beta-methyleneadenosine 5'-diphosphateIBA 10/2002
1	Cytochromes c (Cytochrome c)IBA 08/2002

Therapy/Procedure

4	Therapeutics 01/2019 - 03/2007
2	Immunotherapy 06/2011 - 03/2010
1	Photothermal Therapy 01/2021
1	Radiotherapy 01/2017
1	Stem Cell Transplantation 01/2013
1	Ligation 10/2011
1	Punctures 10/2011
1	Subcutaneous Injections 05/2007